drugset / Trial / NCT00626782

Lucentis Versus Mitomycin C During Glaucoma Surgery

NCT00626782

RandomizedParallel-groupOpen-labelTreatment

Summary

Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known complications of mytomycin C which include late bleb leaks, hypotony and infection.

Timeline

Start
2008-01
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mitomycin (MMC) Unknown 0.4 mg/ml
Subject Ranibizumab Monoclonal antibody 0.05 ml Other
Subject Ranibizumab Monoclonal antibody 0.5 mg Other

Indications